All News
Depends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read Article
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative hidradenitis, and Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, amongst others.
Read Article
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3
Links:
Dr. John Cush RheumNow ( View Tweet)
Lit review of ILD in anti-synthetase syndrome finds no conclusive evidence of effective treatment. 10 studies, 514 pts (68% female); Hi Res CT positive in 87% w/ 49% having NSIP pattern. 48% Jo-1+, 28% Ro52+. Low improvements w/ RTX (12%), CYC (17%). https://t.co/oJ0EMAE7d0 https://t.co/bDiA1h9hO7
Dr. John Cush RheumNow ( View Tweet)
Systematic review: RX of macrophage activation syndr (MAS), included 57 reports, 1148 MAS pts (889 sJIA, 137 SLE). Most effective was high-dose GCs, IL-1 (83%) & IFNγ (93%) inhibitors, especially in sJIA-MAS. Also Ciclosporin, etoposide, Ruxolitinib https://t.co/4EnMOnlcYl https://t.co/PQnAZLvVwq
Dr. John Cush RheumNow ( View Tweet)
Inpatient study 5495 Adult Stills Dz (AOSD) hospitalizations (2016–2019). Pts w/ HLH (6.2%) had higher mortality (9% vs 1.5%). Deatjs Independent predictors: DIC (OR 6.1), liver failure (7.2), Infx (3.7), resp failure (6.9),thrombotic microangiopathy (14) https://t.co/BQsbVnw2Ir https://t.co/mbn9JuN7ow
Dr. John Cush RheumNow ( View Tweet)
3 yr German laboratory study of 71,597 laboratory tests, found 238 positive tests for 13 myositis autoAbs in 209 patients. Pos. results due to Idiopathic inflammatory myopathy in 37(18%), other inflammatory rheum Dz 90 (43%) or NO Rheum Dx 82 (39%) https://t.co/KKg0X1AyU1 https://t.co/FfVfufaUm4
Dr. John Cush RheumNow ( View Tweet)
Pollution and Autoimmunity (7.12.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on https://t.co/V10S4oVFsv. https://t.co/c4Eo4EpOj8
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read, comprehensive review of NLRP3 inflammasome & its role in inate immunity (eg, infections), but also lifestyle (obesity, diabetes, NAFLD, heart/lung disease, periodontitis) and autoimmune diseases https://t.co/rCk9ncEsGA https://t.co/qc9eSIAVYe
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
https://t.co/46g8ek286u https://t.co/FEFq4vkiPk
Links:
Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Autoimmune Dz (AID) & myelodysplastic syndrome (MDS) finds AIDs found in 17.5% of MDS pts. With AID, MDS mortality rates ranged 15.3-67%. Why this relationship exists is unclear. https://t.co/SZNH8v2CIT https://t.co/QTGiqUCqqs
Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw
Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG
Dr. John Cush RheumNow ( View Tweet)
Systemic Score in AOSD to Predict Life-threatening Complications
Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn
Dr. Antoni Chan synovialjoints ( View Tweet)
NEW biomarkers in #MAS
1️⃣ IL-18 (available at some 🏥)⭐️
2️⃣ S100A12
3️⃣ CXCL9/10
🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder!
🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷
#macrophage
#EULAR2024
#genetics
#rheumx https://t.co/Uot3JjrWs8
Links:
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Potential efficacy of JAK inhibitors in VEXAS syndrome
#EULAR2024
NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
